Ticker League

EBITDA for Insulet (PODD)

Latest filings through · Reported

Metric

TTM

$575.00M

YoY change

+25.6%

5Y CAGR

+37.0%

Peak year (2025)

$532.30M

EBITDA history chart for Insulet (PODD) from 2002 to 2025

Latest: $532.30M

EBITDA growth chart for Insulet (PODD) from 2002 to 2025

Latest: +25.6%

EBITDA history table for Insulet (PODD) from 2002 to 2025

  • 2025$532.30M+25.6%
  • 2024$423.70M+30.9%
  • 2023$323.60M+196.9%
  • 2022$109.00M-21.9%
  • 2021$139.60M+26.6%
  • 2020$110.30M+48.7%
  • 2019$74.20M+57.5%
  • 2018$47.10M+635.9%
  • 2017$6.40M+356.2%
  • 2016$1.40M-104.3%
  • 2015−$32.84M+55.8%
  • 2014−$21.08M+30.3%
  • 2013−$16.18M-34.8%
  • 2012−$24.83M-26.6%
  • 2011−$33.83M+1.3%
  • 2010−$33.39M-38.1%
  • 2009−$53.90M-27.9%
  • 2008−$74.80M+52.9%
  • 2007−$48.92M+52.9%
  • 2006−$32.01M+57.9%
  • 2005−$20.27M+50.2%
  • 2004−$13.50M+12.3%
  • 2003−$12.01M-5.2%
  • 2002−$12.67M—

EBITDA values are taken from Insulet's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Insulet (PODD)

According to Insulet's latest reported financial statements, the company's current EBITDA (TTM) is $575.00M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

In 2025, Insulet (PODD) EBITDA totalled $532.30M – grew 25.6% year-over-year.

Looking at the 2020–2025 (5 years) stretch, Insulet EBITDA compounded at +37.0% per year, sustaining 3 straight years of year-over-year growth.

The record annual EBITDA stands at $532.30M, reached in 2025; the historical low of −$74.80M was recorded in 2008.

Insulet EBITDA by Year

Insulet EBITDA 2025: $532.30M

Insulet posted EBITDA of $532.30M in 2025, grew 25.6% from 2024. This figure represents the highest annual value in the available history.

Insulet EBITDA 2024: $423.70M

In 2024, Insulet reported EBITDA of $423.70M, surged 30.9% from 2023.

Insulet EBITDA 2023: $323.60M

Insulet EBITDA in 2023 was $323.60M, surged 196.9% from 2022.

Insulet EBITDA 2022: $109.00M

2022's EBITDA for Insulet came in at $109.00M, declined 21.9% below 2021.

Insulet EBITDA 2021: $139.60M

Insulet EBITDA in 2021 was $139.60M.

See more financial history for Insulet (PODD).

Sector peers by EBITDA

Healthcare peers of Insulet (PODD), ranked by their latest EBITDA

Frequently asked questions

Insulet (PODD) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return